{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:16:35Z","timestamp":1770286595323,"version":"3.49.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11897-020-00463-1","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T02:02:23Z","timestamp":1591149743000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of Sacubitril-Valsartan on Markers of Glomerular Function"],"prefix":"10.1007","volume":"17","author":[{"given":"Gregorio","family":"Tersalvi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Dauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"8","key":"463_CR1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891\u2013975.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"463_CR2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"5","key":"463_CR3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"\u2022\u2022 Voors AA, Gori M, LCY L, Claggett B, Zile MR, Pieske B, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17(5):510\u20137 Post-hoc analysis of the PARAMOUNT trial, showing that sacubitril\/valsartan led to a slower rate of decrease in eGFR and to a slight increase in UACR compared to ARB in patients with HFpEF.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"463_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"\u2022\u2022 Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489\u201398 Post-hoc analysis of the PARADIGM-HF trial, showing that sacubitril\/valsartan led to a slower rate of decrease in eGFR and to a slight increase in UACR compared to ACE-I in patients with HFrEF.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"463_CR5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11739-019-02111-6","volume":"14","author":"F Spannella","year":"2019","unstructured":"\u2022 Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, et al. Renal effects of sacubitril\/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287\u201397 A real-life study showing that patients on sacubitril\/valsartan had a significant improvement in eGFR after 12 months, compared to historical controls. A greater benefit in subjects aged < 65 years and patients with CKD was also observed.","journal-title":"Intern Emerg Med"},{"key":"463_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/170594","volume":"2012","author":"AT Layton","year":"2012","unstructured":"Layton AT. Modeling transport and flow regulatory mechanisms of the kidney. ISRN Biomath. 2012;2012:1\u201318.","journal-title":"ISRN Biomath"},{"issue":"4","key":"463_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1152\/nips.01442.2003","volume":"18","author":"V Vallon","year":"2003","unstructured":"Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. Physiology. 2003;18(4):169\u201374.","journal-title":"Physiology."},{"issue":"24","key":"463_CR8","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","volume":"38","author":"W Mullens","year":"2017","unstructured":"Mullens W, Verbrugge FH, Nijst P, Tang WHW. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J. 2017;38(24):1872\u201382.","journal-title":"Eur Heart J"},{"issue":"2","key":"463_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ejhf.35","volume":"16","author":"FH Verbrugge","year":"2014","unstructured":"Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WHW, et al. The kidney in congestive heart failure: \u201care natriuresis, sodium, and diuretics really the good, the bad and the ugly?\u201d. Eur J Heart Fail. 2014;16(2):133\u201342.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"463_CR10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.mnh.0000444813.72626.88","volume":"23","author":"EJ Lamb","year":"2014","unstructured":"Lamb EJ, Stevens PE. Estimating and measuring glomerular filtration rate: methods of measurement and markers for estimation. Curr Opin Nephrol Hypertens. 2014;23(3):258\u201366.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"463_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020:ejhf.1697 Recent expert consensus paper of the Heart Failure Association, which incorporates insights into the interpretation of renal function assessment in the different heart failure states.","DOI":"10.1002\/ejhf.1697"},{"issue":"2","key":"463_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola V-P, Mebazaa A, Brunner La Rocca H-P, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology: diuretics in heart failure. Eur J Heart Fail. 2019;21(2):137\u201355.","journal-title":"Eur J Heart Fail"},{"key":"463_CR13","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-21033-5","volume-title":"Cardiorenal syndrome in heart failure","author":"WHW Tang","year":"2020","unstructured":"Tang WHW, Verbrugge FH, Mullens W. Cardiorenal syndrome in heart failure. Cham: Springer International Publishing; 2020."},{"issue":"7","key":"463_CR14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","volume":"53","author":"K Damman","year":"2009","unstructured":"Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"463_CR15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","volume":"53","author":"W Mullens","year":"2009","unstructured":"Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"463_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/eurheartj\/ehi020","volume":"26","author":"LG Bongartz","year":"2005","unstructured":"Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: \u201cGuyton revisited.\u201d. Eur Heart J. 2005;26(1):11\u20137.","journal-title":"Eur Heart J"},{"issue":"4 Pt 2","key":"463_CR17","first-page":"R896","volume":"268","author":"J Liao","year":"1995","unstructured":"Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Phys. 1995;268(4 Pt 2):R896\u2013901.","journal-title":"Am J Phys"},{"issue":"1","key":"463_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.RES.0000109412.80157.7D","volume":"94","author":"T Bleeke","year":"2004","unstructured":"Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94(1):37\u201345.","journal-title":"Circ Res"},{"issue":"6","key":"463_CR19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.HYP.36.6.1083","volume":"36","author":"GF DiBona","year":"2000","unstructured":"DiBona GF. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension. 2000;36(6):1083\u20138.","journal-title":"Hypertension."},{"issue":"9","key":"463_CR20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2362.2003.01222.x","volume":"33","author":"A Charloux","year":"2003","unstructured":"Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Investig. 2003;33(9):769\u201378.","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"463_CR21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0735-1097(99)00608-7","volume":"35","author":"DL Dries","year":"2000","unstructured":"Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35(3):681\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"463_CR22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","volume":"102","author":"HL Hillege","year":"2000","unstructured":"Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203\u201310.","journal-title":"Circulation."},{"issue":"1","key":"463_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCHEARTFAILURE.113.000556","volume":"7","author":"MM Givertz","year":"2014","unstructured":"Givertz MM, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, et al. Renal function trajectories and clinical outcomes in acute heart failure. Circ Heart Fail. 2014;7(1):59\u201367.","journal-title":"Circ Heart Fail"},{"issue":"5","key":"463_CR24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","volume":"113","author":"HL Hillege","year":"2006","unstructured":"Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671\u20138.","journal-title":"Circulation."},{"issue":"1","key":"463_CR25","doi-asserted-by":"crossref","first-page":"e000324","DOI":"10.1136\/openhrt-2015-000324","volume":"3","author":"I L\u00f6fman","year":"2016","unstructured":"L\u00f6fman I, Szummer K, Hagerman I, Dahlstr\u00f6m U, Lund LH, Jernberg T. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3(1):e000324.","journal-title":"Open Heart"},{"issue":"16","key":"463_CR26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.109.853648","volume":"120","author":"IS Anand","year":"2009","unstructured":"Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120(16):1577\u201384.","journal-title":"Circulation."},{"issue":"7","key":"463_CR27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ejim.2013.06.003","volume":"24","author":"J Casado","year":"2013","unstructured":"Casado J, Montero M, Formiga F, Carrera M, Urrutia A, Ar\u00e9valo JC, et al. Clinical characteristics and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. Eur J Intern Med. 2013;24(7):677\u201383.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"463_CR28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","volume":"5","author":"FA McAlister","year":"2012","unstructured":"McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new chronic kidney disease-epidemiology collaboration group formula. Circ Heart Fail. 2012;5(3):309\u201314.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"463_CR29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijcard.2009.09.529","volume":"147","author":"D Rusinaru","year":"2011","unstructured":"Rusinaru D, Buiciuc O, Houpe D, Tribouilloy C. Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. Int J Cardiol. 2011;147(2):278\u201382.","journal-title":"Int J Cardiol"},{"issue":"11","key":"463_CR30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","volume":"59","author":"S Ather","year":"2012","unstructured":"Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998\u20131005.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"463_CR31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MAE, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455\u201369.","journal-title":"Eur Heart J"},{"issue":"2","key":"463_CR32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1152\/advan.00177.2016","volume":"41","author":"PCY Wong","year":"2017","unstructured":"Wong PCY, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017;41(2):179\u201385.","journal-title":"Adv Physiol Educ"},{"issue":"3","key":"463_CR33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1152\/physrev.1990.70.3.665","volume":"70","author":"BM Brenner","year":"1990","unstructured":"Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 1990;70(3):665\u201399.","journal-title":"Physiol Rev"},{"issue":"3 Pt 2","key":"463_CR34","first-page":"F415","volume":"255","author":"K Ohishi","year":"1988","unstructured":"Ohishi K, Hishida A, Honda N. Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles. Am J Phys. 1988;255(3 Pt 2):F415\u201320.","journal-title":"Am J Phys"},{"issue":"3 Pt 2","key":"463_CR35","first-page":"F440","volume":"254","author":"PJ Veldkamp","year":"1988","unstructured":"Veldkamp PJ, Carmines PK, Inscho EW, Navar LG. Direct evaluation of the microvascular actions of ANP in juxtamedullary nephrons. Am J Phys. 1988;254(3 Pt 2):F440\u20134.","journal-title":"Am J Phys"},{"issue":"11","key":"463_CR36","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","volume":"278","author":"LR Potter","year":"2011","unstructured":"Potter LR. Natriuretic peptide metabolism, clearance and degradation: natriuretic peptide metabolism. FEBS J. 2011;278(11):1808\u201317.","journal-title":"FEBS J"},{"issue":"3","key":"463_CR37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1042\/bj1370477","volume":"137","author":"MA Kerr","year":"1974","unstructured":"Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J. 1974;137(3):477\u201388.","journal-title":"Biochem J"},{"issue":"12","key":"463_CR38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","volume":"34","author":"S Mangiafico","year":"2012","unstructured":"Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2012;34(12):886\u201393.","journal-title":"Eur Heart J"},{"issue":"5","key":"463_CR39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1096\/fasebj.11.5.9141502","volume":"11","author":"AJ Turner","year":"1997","unstructured":"Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997;11(5):355\u201364.","journal-title":"FASEB J"},{"issue":"1","key":"463_CR40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/bmme.1997.2584","volume":"61","author":"Y Watanabe","year":"1997","unstructured":"Watanabe Y, Nakajima K, Shimamori Y, Fujimoto Y. Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral Endopeptidase 24.11. Biochem Mol Med. 1997;61(1):47\u201351.","journal-title":"Biochem Mol Med"},{"issue":"1","key":"463_CR41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1042\/bj2910083","volume":"291","author":"AJ Kenny","year":"1993","unstructured":"Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(1):83\u20138.","journal-title":"Biochem J"},{"issue":"1","key":"463_CR42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1042\/bj2410237","volume":"241","author":"SL Stephenson","year":"1987","unstructured":"Stephenson SL, Kenny AJ. Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J. 1987;241(1):237\u201347.","journal-title":"Biochem J"},{"issue":"4","key":"463_CR43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0196-9781(91)90132-9","volume":"12","author":"C Fagny","year":"1991","unstructured":"Fagny C, Michel A, L\u00e9onard I, Berkenboom G, Fontaine J, Deschodt-Lanckman M. In vitro degradation of endothelin-1 by endopeptidase 24.11 (enkephalinase). Peptides. 1991;12(4):773\u20138.","journal-title":"Peptides."},{"issue":"24","key":"463_CR44","doi-asserted-by":"crossref","first-page":"14150","DOI":"10.1016\/S0021-9258(18)77280-3","volume":"265","author":"J Vijayaraghavan","year":"1990","unstructured":"Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990;265(24):14150\u20135.","journal-title":"J Biol Chem"},{"issue":"8","key":"463_CR45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s11739-019-02149-6","volume":"14","author":"G Mul\u00e8","year":"2019","unstructured":"Mul\u00e8 G, Sorce A, Nardi E, Geraci G, Cottone S. The nephroprotective effect of sacubitril\/valsartan in heart failure: insights from the real-life clinical setting. Intern Emerg Med. 2019;14(8):1205\u20138.","journal-title":"Intern Emerg Med"},{"issue":"9851","key":"463_CR46","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387\u201395.","journal-title":"Lancet."},{"key":"463_CR47","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1046\/j.1523-1755.2000.07505.x","volume":"57","author":"AB Fogo","year":"2000","unstructured":"Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int. 2000;57:S15\u201321.","journal-title":"Kidney Int"},{"issue":"10","key":"463_CR48","doi-asserted-by":"crossref","first-page":"F1399","DOI":"10.1152\/ajprenal.00385.2011","volume":"303","author":"LMA Lessa","year":"2012","unstructured":"Lessa LMA, Carraro-Lacroix LR, Crajoinas RO, Bezerra CN, Dariolli R, Girardi ACC, et al. Mechanisms underlying the inhibitory effects of uroguanylin on NHE3 transport activity in renal proximal tubule. Am J Physiol Renal Physiol. 2012;303(10):F1399\u2013408.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"463_CR49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jchf.2018.02.017","volume":"6","author":"W Mullens","year":"2018","unstructured":"Mullens W, Martens P. Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure. JACC Heart Fail. 2018;6(6):499\u2013502.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"463_CR50","first-page":"5473","volume":"9","author":"W Jing","year":"2017","unstructured":"Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, et al. LCZ696 (Sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am J Transl Res. 2017;9(12):5473\u201384.","journal-title":"Am J Transl Res"},{"key":"463_CR51","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","volume":"99","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;99:S57\u201365.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"463_CR52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mce.2008.11.003","volume":"302","author":"AM Garrido","year":"2009","unstructured":"Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol. 2009;302(2):148\u201358.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"463_CR53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.110.175828","volume":"337","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Sato T, Rodr\u00edguez-Iturbe B, Vaziri ND. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J Pharmacol Exp Ther. 2011;337(3):583\u201390.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"463_CR54","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000098148","volume":"26","author":"MI Ros\u00f3n","year":"2006","unstructured":"Ros\u00f3n MI, Toblli JE, Della Penna SL, Gorzalczany S, Pandolfo M, Cavallero S, et al. Renal protective role of atrial natriuretic peptide in acute sodium overload-induced inflammatory response. Am J Nephrol. 2006;26(6):590\u2013601.","journal-title":"Am J Nephrol"},{"issue":"5\u20136","key":"463_CR55","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000020623","volume":"7","author":"PK Chatterjee","year":"1999","unstructured":"Chatterjee PK, Hawksworth GM, McLay JS. Cytokine-stimulated nitric oxide production in the human renal proximal tubule and its modulation by natriuretic peptides: a novel immunomodulatory mechanism? Exp Nephrol. 1999;7(5\u20136):438\u201348.","journal-title":"Exp Nephrol"},{"issue":"2","key":"463_CR56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0168-8278(00)80364-5","volume":"33","author":"AK Kiemer","year":"2000","unstructured":"Kiemer AK, Vollmar AM, Bilzer M, Gerwig T, Gerbes AL. Atrial natriuretic peptide reduces expression of TNF-alpha mRNA during reperfusion of the rat liver upon decreased activation of NF-kappaB and AP-1. J Hepatol. 2000;33(2):236\u201346.","journal-title":"J Hepatol"},{"issue":"2","key":"463_CR57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FJC.0000000000000603","volume":"72","author":"L Vicent","year":"2018","unstructured":"Vicent L, Esteban-Fern\u00e1ndez A, G\u00f3mez-Bueno M, De-Juan J, D\u00edez-Villanueva P, Iniesta \u00c1M, et al. Clinical profile of a nonselected population treated with Sacubitril\/valsartan is different from PARADIGM-HF trial. J Cardiovasc Pharmacol. 2018;72(2):112\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"463_CR58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"H-Y Chang","year":"2019","unstructured":"Chang H-Y, Feng A-N, Fong M-C, Hsueh C-W, Lai W-T, Huang K-C, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372\u201380.","journal-title":"J Cardiol"},{"issue":"15","key":"463_CR59","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"\u2022\u2022 Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial. Circulation. 2018;138(15):1505\u201314 Randomized controlled trial testing sacubitril\/valsartan versus ARB in patients with CKD, mostly without HF. After 12 months, no difference in eGFR and albuminuria were found between the two groups.","journal-title":"Circulation"},{"issue":"15","key":"463_CR60","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCULATIONAHA.118.036523","volume":"138","author":"M James","year":"2018","unstructured":"James M, Manns B. Neprilysin inhibition and effects on kidney function and surrogates of cardiovascular risk in chronic kidney disease. Circulation. 2018;138(15):1515\u20138.","journal-title":"Circulation."},{"issue":"4","key":"463_CR61","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","volume":"62","author":"E Braunwald","year":"2019","unstructured":"Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019;62(4):298\u2013302.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"463_CR62","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1046\/j.1523-1747.2002.19618.x","volume":"119","author":"M Antezana","year":"2002","unstructured":"Antezana M, Sullivan SR, Usui M, Gibran N, Spenny M, Larsen J, et al. Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol. 2002;119(6):1400\u20134.","journal-title":"J Invest Dermatol"},{"key":"463_CR63","first-page":"977","volume":"12","author":"H Hara","year":"2006","unstructured":"Hara H, Oh-hashi K, Yoneda S, Shimazawa M, Inatani M, Tanihara H, et al. Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy. Mol Vis. 2006;12:977\u201382.","journal-title":"Mol Vis"},{"issue":"5","key":"463_CR64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1096-9136(199805)15:5<375::AID-DIA585>3.0.CO;2-N","volume":"15","author":"PD Chattington","year":"1998","unstructured":"Chattington PD, Anderson JV, Rees LH, Leese GP, Peters JR, Vora JP. Atrial natriuretic peptide in type 2 diabetes mellitus: response to a physiological mixed meal and relationship to renal function. Diabet Med. 1998;15(5):375\u20139.","journal-title":"Diabet Med"},{"issue":"5","key":"463_CR65","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oxfordjournals.ndt.a027401","volume":"11","author":"RO Gans","year":"1996","unstructured":"Gans RO, Bilo HJ, Donker AJ. The renal response to exogenous insulin in non-insulin-dependent diabetes mellitus in relation to blood pressure and cardiovascular hormonal status. Nephrol Dial Transplant. 1996;11(5):794\u2013802.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"463_CR66","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","volume":"6","author":"M Packer","year":"2018","unstructured":"\u2022 Packer M, Claggett B, Lefkowitz MP, JJV MM, Rouleau JL, Solomon SD, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6(7):547\u201354 Secondary analysis of the PARADIGM-HF trial, showing that the magnitude of the benefit of sacubitril\/valsartan on slowing eGFR deterioration was larger in patients with diabetes versus those without.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"463_CR67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"463_CR68","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjcard.2008.04.048","volume":"102","author":"J Grewal","year":"2008","unstructured":"Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, et al. Usefulness of N-terminal pro\u2013brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102(6):733\u20137.","journal-title":"Am J Cardiol"},{"issue":"7","key":"463_CR69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","volume":"126","author":"L van Heerebeek","year":"2012","unstructured":"van Heerebeek L, Hamdani N, Falc\u00e3o-Pires I, Leite-Moreira AF, Begieneman MPV, Bronzwaer JGF, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830\u20139.","journal-title":"Circulation."},{"issue":"17","key":"463_CR70","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-020-00463-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-020-00463-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-020-00463-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T23:59:52Z","timestamp":1622678392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-020-00463-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1007\/s11897-020-00463-1","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"3 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No potential conflicts of interest relevant to this article were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}